Company Overview
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -61.34% |
| 6 Months: | -32.85% |
| 3 Months: | -50.93% |
| 1 Month: | -35.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross5d ago
- RSI (14)23.80 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 61.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 24 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LTRN Lantern Pharma Inc. PHARMA | 1.84 | -1.13 | $23.52M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | - | -833.42K | -1.70M | - | -2.48M | -4.15M | -4.07M | -4.39M | -2.15M | -4.29M | -5.19M | -3.52M | -5.73M | -5.41M | -5.18M | -4.77M | -4.65M | -4.35M | -3.41M |
| Net Income | -629.39K | -669.65K | -477.28K | -833.42K | -1.70M | -2.45M | -2.32M | -4.05M | -4.12M | -4.49M | -2.26M | -3.87M | -4.75M | -3.16M | -5.44M | -4.96M | -4.51M | -4.54M | -4.33M | -4.18M | -3.33M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.41 | -0.21 | -0.36 | -0.44 | -0.29 | -0.51 | -0.46 | -0.42 | -0.42 | -0.40 | -0.39 | -0.30 |
| R&D Expense | - | - | 137.10K | 157.02K | 600.77K | 1.28M | 1.16M | 2.96M | 2.66M | 2.99M | 702.30K | 2.55M | 3.56M | 2.21M | 4.25M | 3.89M | 3.72M | 3.26M | 3.07M | 2.44M | 1.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -12.59M | -14.43M | -17.88M | -22.22M | -17.98M |
| Net Income | -2.43M | -5.91M | -12.36M | -14.26M | -15.96M | -20.78M | -17.12M |
| Diluted EPS | - | - | - | -1.31 | -1.47 | -1.93 | -1.57 |
| R&D Expense | - | 2.24M | 7.57M | 8.60M | 11.89M | 16.13M | 11.51M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.43M | 20.36M | 73.95M | 58.84M | 43.65M | 25.57M | 11.04M |
| Total Equity | -201.80K | 943.28K | 19.70M | 71.57M | 56.04M | 40.91M | 21.19M | 6.53M |
| Cash & Equivalents | 445.16K | 1.23M | 19.23M | 51.52M | 37.20M | 21.94M | 7.51M | 4.42M |
| Total Liabilities | - | 489.29K | 660.84K | 2.38M | 2.80M | 2.74M | 4.38M | 4.50M |
| Current Liabilities | - | 489.29K | 552.34K | 2.33M | 2.80M | 2.68M | 4.33M | 4.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.13M | -5.65M | -10.59M | -12.77M | -14.35M | -17.81M | -15.68M |
| Investing Cash Flow | -5.72K | -16.14K | -19.53M | 179.27K | -930.21K | 3.37M | 11.06M |
| Financing Cash Flow | 2.92M | 23.66M | 63.42M | -2.18M | -500.00K | 66.71K | 1.50M |
| Capital Expenditure | - | - | -15.50K | -27.84K | -18.73K | -12.60K | -1.72K |
| Free Cash Flow | - | - | -10.61M | -12.80M | -14.37M | -17.83M | -15.68M |
| Share Buybacks | - | - | 939.67K | 2.48M | 500.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | -257.4% | -30.0% | -17.3% | -25.4% | -39.0% | -98.1% | -262.0% |
| ROCE % | - | - | -17.6% | -25.8% | -43.6% | -104.6% | -275.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Empery Asset Management, LP | 6.59% | 842.67K | $1.31M |
| 2 | CM Management, LLC | 3.91% | 500.00K | $775.00K |
| 3 | Vanguard Capital Management LLC | 3.33% | 425.12K | $658.93K |
| 4 | Renaissance Technologies, LLC | 2.28% | 291.04K | $451.11K |
| 5 | Bios Capital Management, LP | 1.95% | 249.40K | $386.56K |
| 6 | Geode Capital Management, LLC | 0.80% | 102.82K | $159.37K |
| 7 | Vanguard Fiduciary Trust Co | 0.39% | 49.95K | $77.42K |
| 8 | Westside Investment Management, Inc. | 0.37% | 47.85K | $74.17K |
| 9 | Citadel Advisors Llc | 0.37% | 47.90K | $74.24K |
| 10 | Quadrature Capital Ltd | 0.31% | 39.59K | $61.37K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LTRN
Lantern Pharma Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQQVZiX0t3R1lWOEV0alpkandYOFM3a3VRblRJLXY4TF9nYlNDclh4T2FLelhiN0Y1WDV5b2Z4TTNicnczM3NQQ1FTd0NUeEdnb0NXU1BpbFRnWjNIQXk5Yi05NWR0ZUViTUZqX3RHZ0hWc2l2dWt6cjdBYjR4alQ2YjVIdmRBMDFVekNweW…
Three Genes Anchor Lantern Pharma's Newly Allowed LP-184 Patent - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOUWxGcERZeHN6bUw2M1ROUG5sRnhIdGh5X0o5MkxPSEp0cXBpODJ5TDVsUnlxWkdoVE1wZm9YSmo0R2ZMeHNlR19CbmVrRkZERXZQMXl3Y2dDRThZdFRKOEQtLXR2WkxuNnBtQXhoMDBaNDc0UmJiZjEyYXN4VWtvUGF6NUx6Yy1VbVpyRU…
LTRN Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBCWWtxYTZ3djNpZGpmaTVCQ1pZSEFDT3NpbDEwa1N3TUxjdHctZFVETnA0TzJuRVcxa1MxY3A1VXJVcjlqRjFGbjlTRFBRUXc4UmtKeDVCR195VXhvS25yM1MtMmtnUS0tc183aWFrMUpXOUJkYW82VkhR?oc=5" target="_blank">LTR…
LANTERN PHARMA ($LTRN) Releases Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxObm1tSzNPaGtMLVptNk9HRlpYSVpaWW1nTDlHMXBTcUtLa3FIT0hYRDZhUE9KY2FqVE9OT3NrM1pUUC1sVmhnbnVkUWt0cWxMeTUzZ3RiRTAzNXdHNlJzN2VUQ0plcGdWLURHSUVsNXRneUtJUFp6T2RmM2N5S1dsUnptVVM3QTItVUU2bm…
Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Sahm
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPUzcxbXBTOHg5andLZXlNWElLc0dtd1BZNng0OG9pRmRHS2hKdHVfbWdMdExORTIxd3hMVnNza0E5MkFBNkYzZ1V2WV9PdXBNSTN1ZXd2dVE5NW1oMXBIM0xBcFhTeUc2ZU1idjhuaG5sQm9uVmYyQ25NOFkzZ2ZKc3ktbFp1NUNnN1ZFQ2…
Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNeG0yeWdqRTdOdldpckJaMzRPbllkLXVNSF92VmVZZFZBeWl6QXg1NHA0d1U2REZUV2V2YTdEWnJvLUdHODNDcVpuU2ZfOVAtUDVaWmJfQUU4V0tZY3JZYU9HUDUtQkRjVk1UMGJ1TThfYXdtMEotbEhpTERCMU9OcFRtcUkyZDd6ZmF3NF…
LTRN — Frequently Asked Questions
What is the current share price of Lantern Pharma Inc. (LTRN)?
As of 2026-09-19 21:16 PDT, Lantern Pharma Inc. (LTRN) trades at $1.84 on NasdaqCM. Its 52-week range is $1.12 to $4.76.
What is the market capitalisation of LTRN?
Lantern Pharma Inc. (LTRN) has a market capitalisation of $23.52M on NasdaqCM.
What is the P/E ratio of LTRN?
LTRN trades at a trailing price-to-earnings (P/E) ratio of -1.13. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -6.15.
Is LTRN a good stock to buy?
This page provides a data-driven analysis of Lantern Pharma Inc. (LTRN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.